| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Fusion Protein:MARK2-PLA2G16 |
Fusion Protein Summary |
 Fusion gene summary |
| Fusion partner gene information | Fusion gene name: MARK2-PLA2G16 | FusionPDB ID: 51755 | FusionGDB2.0 ID: 51755 | Hgene | Tgene | Gene symbol | MARK2 | PLA2G16 | Gene ID | 2011 | 11145 |
| Gene name | microtubule affinity regulating kinase 2 | phospholipase A and acyltransferase 3 | |
| Synonyms | EMK-1|EMK1|PAR-1|Par-1b|Par1b | AdPLA|H-REV107|H-REV107-1|HRASLS3|HREV107|HREV107-1|HREV107-3|HRSL3|PLA2G16|PLAAT-3 | |
| Cytomap | 11q13.1 | 11q12.3-q13.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | serine/threonine-protein kinase MARK2ELKL motif kinase 1MAP/microtubule affinity-regulating kinase 2PAR1 homolog bSer/Thr protein kinase PAR-1Bserine/threonine protein kinase EMKtesticular tissue protein Li 117 | phospholipase A and acyltransferase 3Ca-independent phospholipase A1/2H-rev 107 protein homologHRAS-like suppressor 1HRAS-like suppressor 3adipose-specific PLA2adipose-specific phospholipase A2group XVI phospholipase A1/A2group XVI phospholipase A | |
| Modification date | 20200329 | 20200313 | |
| UniProtAcc | Q7KZI7 | . | |
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000315032, ENST00000350490, ENST00000361128, ENST00000377809, ENST00000402010, ENST00000413835, ENST00000502399, ENST00000508192, ENST00000377810, ENST00000408948, ENST00000425897, ENST00000509502, ENST00000513765, | ENST00000394613, ENST00000323646, ENST00000415826, |
| Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 13 X 9 X 11=1287 | 8 X 7 X 4=224 |
| # samples | 21 | 8 | |
| ** MAII score | log2(21/1287*10)=-2.61555082055458 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(8/224*10)=-1.48542682717024 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context (manual curation of fusion genes in FusionPDB) | PubMed: MARK2 [Title/Abstract] AND PLA2G16 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | MARK2(63607032)-PLA2G16(63342518), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | MARK2-PLA2G16 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. MARK2-PLA2G16 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. MARK2-PLA2G16 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. MARK2-PLA2G16 seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF. MARK2-PLA2G16 seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF. MARK2-PLA2G16 seems lost the major protein functional domain in Tgene partner, which is a tumor suppressor due to the frame-shifted ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | MARK2 | GO:0006468 | protein phosphorylation | 14976552 |
| Hgene | MARK2 | GO:0010976 | positive regulation of neuron projection development | 12429843 |
| Hgene | MARK2 | GO:0018105 | peptidyl-serine phosphorylation | 10542369|16717194 |
| Hgene | MARK2 | GO:0030010 | establishment of cell polarity | 12429843 |
| Hgene | MARK2 | GO:0035556 | intracellular signal transduction | 14976552 |
| Hgene | MARK2 | GO:0045197 | establishment or maintenance of epithelial cell apical/basal polarity | 15324659 |
| Hgene | MARK2 | GO:0070507 | regulation of microtubule cytoskeleton organization | 10542369 |
| Tgene | PLA2G16 | GO:0006644 | phospholipid metabolic process | 20100577 |
| Tgene | PLA2G16 | GO:0070292 | N-acylphosphatidylethanolamine metabolic process | 22825852 |
| Fusion gene breakpoints across MARK2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across PLA2G16 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
Top |
Fusion Gene Sample Information |
| Fusion gene information from FusionGDB2.0. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | STAD | TCGA-BR-A44T-01A | MARK2 | chr11 | 63607032 | + | PLA2G16 | chr11 | 63342518 | - |
Top |
Fusion ORF Analysis |
| Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000377809 | MARK2 | chr11 | 63607032 | + | ENST00000415826 | PLA2G16 | chr11 | 63342518 | - | 1206 | 633 | 68 | 493 | 141 |
| ENST00000402010 | MARK2 | chr11 | 63607032 | + | ENST00000415826 | PLA2G16 | chr11 | 63342518 | - | 1206 | 633 | 68 | 493 | 141 |
| ENST00000413835 | MARK2 | chr11 | 63607032 | + | ENST00000415826 | PLA2G16 | chr11 | 63342518 | - | 1206 | 633 | 68 | 493 | 141 |
| ENST00000315032 | MARK2 | chr11 | 63607032 | + | ENST00000415826 | PLA2G16 | chr11 | 63342518 | - | 1206 | 633 | 68 | 493 | 141 |
| ENST00000508192 | MARK2 | chr11 | 63607032 | + | ENST00000415826 | PLA2G16 | chr11 | 63342518 | - | 1129 | 556 | 15 | 416 | 133 |
| ENST00000361128 | MARK2 | chr11 | 63607032 | + | ENST00000415826 | PLA2G16 | chr11 | 63342518 | - | 1129 | 556 | 15 | 416 | 133 |
| ENST00000350490 | MARK2 | chr11 | 63607032 | + | ENST00000415826 | PLA2G16 | chr11 | 63342518 | - | 1041 | 468 | 610 | 233 | 125 |
| ENST00000502399 | MARK2 | chr11 | 63607032 | + | ENST00000415826 | PLA2G16 | chr11 | 63342518 | - | 839 | 266 | 408 | 31 | 125 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000377809 | ENST00000415826 | MARK2 | chr11 | 63607032 | + | PLA2G16 | chr11 | 63342518 | - | 0.5288704 | 0.47112957 |
| ENST00000402010 | ENST00000415826 | MARK2 | chr11 | 63607032 | + | PLA2G16 | chr11 | 63342518 | - | 0.5288704 | 0.47112957 |
| ENST00000413835 | ENST00000415826 | MARK2 | chr11 | 63607032 | + | PLA2G16 | chr11 | 63342518 | - | 0.5288704 | 0.47112957 |
| ENST00000315032 | ENST00000415826 | MARK2 | chr11 | 63607032 | + | PLA2G16 | chr11 | 63342518 | - | 0.5288704 | 0.47112957 |
| ENST00000508192 | ENST00000415826 | MARK2 | chr11 | 63607032 | + | PLA2G16 | chr11 | 63342518 | - | 0.21254049 | 0.78745955 |
| ENST00000361128 | ENST00000415826 | MARK2 | chr11 | 63607032 | + | PLA2G16 | chr11 | 63342518 | - | 0.21254049 | 0.78745955 |
| ENST00000350490 | ENST00000415826 | MARK2 | chr11 | 63607032 | + | PLA2G16 | chr11 | 63342518 | - | 0.23851985 | 0.76148015 |
| ENST00000502399 | ENST00000415826 | MARK2 | chr11 | 63607032 | + | PLA2G16 | chr11 | 63342518 | - | 0.27537215 | 0.72462785 |
Top |
Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP >51755_51755_1_MARK2-PLA2G16_MARK2_chr11_63607032_ENST00000315032_PLA2G16_chr11_63342518_ENST00000415826_length(amino acids)=141AA_BP= MFPEFTRSLWPGGEGAPHLPFLAASDVSGCCRRKEPRAGGGGGHVGSSRSGGGCLCAGRGAVPLRAGEERGRRPAAAAESRRSGAARPKG -------------------------------------------------------------- >51755_51755_2_MARK2-PLA2G16_MARK2_chr11_63607032_ENST00000350490_PLA2G16_chr11_63342518_ENST00000415826_length(amino acids)=125AA_BP=1 MMYKVIADRTVFFSYCFCRLFLENMTPIRLMAAKPIPATLAAMMTSLTCSVSLSFSVGRGVRALDMAPVSRGREPRSLEEGREGKARSPA -------------------------------------------------------------- >51755_51755_3_MARK2-PLA2G16_MARK2_chr11_63607032_ENST00000361128_PLA2G16_chr11_63342518_ENST00000415826_length(amino acids)=133AA_BP= MWPGGEGAPHLPFLAASDVSGCCRRKEPRAGGGGGHVGSSRSGGGCLCAGRGAVPLRAGEERGRRPAAAAESRRSGAARPKGGTAQPGVG -------------------------------------------------------------- >51755_51755_4_MARK2-PLA2G16_MARK2_chr11_63607032_ENST00000377809_PLA2G16_chr11_63342518_ENST00000415826_length(amino acids)=141AA_BP= MFPEFTRSLWPGGEGAPHLPFLAASDVSGCCRRKEPRAGGGGGHVGSSRSGGGCLCAGRGAVPLRAGEERGRRPAAAAESRRSGAARPKG -------------------------------------------------------------- >51755_51755_5_MARK2-PLA2G16_MARK2_chr11_63607032_ENST00000402010_PLA2G16_chr11_63342518_ENST00000415826_length(amino acids)=141AA_BP= MFPEFTRSLWPGGEGAPHLPFLAASDVSGCCRRKEPRAGGGGGHVGSSRSGGGCLCAGRGAVPLRAGEERGRRPAAAAESRRSGAARPKG -------------------------------------------------------------- >51755_51755_6_MARK2-PLA2G16_MARK2_chr11_63607032_ENST00000413835_PLA2G16_chr11_63342518_ENST00000415826_length(amino acids)=141AA_BP= MFPEFTRSLWPGGEGAPHLPFLAASDVSGCCRRKEPRAGGGGGHVGSSRSGGGCLCAGRGAVPLRAGEERGRRPAAAAESRRSGAARPKG -------------------------------------------------------------- >51755_51755_7_MARK2-PLA2G16_MARK2_chr11_63607032_ENST00000502399_PLA2G16_chr11_63342518_ENST00000415826_length(amino acids)=125AA_BP=1 MMYKVIADRTVFFSYCFCRLFLENMTPIRLMAAKPIPATLAAMMTSLTCSVSLSFSVGRGVRALDMAPVSRGREPRSLEEGREGKARSPA -------------------------------------------------------------- >51755_51755_8_MARK2-PLA2G16_MARK2_chr11_63607032_ENST00000508192_PLA2G16_chr11_63342518_ENST00000415826_length(amino acids)=133AA_BP= MWPGGEGAPHLPFLAASDVSGCCRRKEPRAGGGGGHVGSSRSGGGCLCAGRGAVPLRAGEERGRRPAAAAESRRSGAARPKGGTAQPGVG -------------------------------------------------------------- |
Top |
Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr11:63607032/chr11:63342518) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| MARK2 | . |
| FUNCTION: Serine/threonine-protein kinase (PubMed:23666762). Involved in cell polarity and microtubule dynamics regulation. Phosphorylates CRTC2/TORC2, DCX, HDAC7, KIF13B, MAP2, MAP4 and RAB11FIP2. Phosphorylates the microtubule-associated protein MAPT/TAU (PubMed:23666762). Plays a key role in cell polarity by phosphorylating the microtubule-associated proteins MAP2, MAP4 and MAPT/TAU at KXGS motifs, causing detachment from microtubules, and their disassembly. Regulates epithelial cell polarity by phosphorylating RAB11FIP2. Involved in the regulation of neuronal migration through its dual activities in regulating cellular polarity and microtubule dynamics, possibly by phosphorylating and regulating DCX. Regulates axogenesis by phosphorylating KIF13B, promoting interaction between KIF13B and 14-3-3 and inhibiting microtubule-dependent accumulation of KIF13B. Also required for neurite outgrowth and establishment of neuronal polarity. Regulates localization and activity of some histone deacetylases by mediating phosphorylation of HDAC7, promoting subsequent interaction between HDAC7 and 14-3-3 and export from the nucleus. Also acts as a positive regulator of the Wnt signaling pathway, probably by mediating phosphorylation of dishevelled proteins (DVL1, DVL2 and/or DVL3). Modulates the developmental decision to build a columnar versus a hepatic epithelial cell apparently by promoting a switch from a direct to a transcytotic mode of apical protein delivery. Essential for the asymmetric development of membrane domains of polarized epithelial cells. {ECO:0000269|PubMed:11433294, ECO:0000269|PubMed:12429843, ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:15158914, ECO:0000269|PubMed:15324659, ECO:0000269|PubMed:15365179, ECO:0000269|PubMed:16775013, ECO:0000269|PubMed:16980613, ECO:0000269|PubMed:18626018, ECO:0000269|PubMed:20194617, ECO:0000269|PubMed:23666762}. | FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | PLA2G16 | chr11:63607032 | chr11:63342518 | ENST00000323646 | 2 | 4 | 155_162 | 129.0 | 163.0 | Topological domain | Lumenal | |
| Tgene | PLA2G16 | chr11:63607032 | chr11:63342518 | ENST00000415826 | 3 | 5 | 155_162 | 129.0 | 163.0 | Topological domain | Lumenal | |
| Tgene | PLA2G16 | chr11:63607032 | chr11:63342518 | ENST00000323646 | 2 | 4 | 134_154 | 129.0 | 163.0 | Transmembrane | Helical | |
| Tgene | PLA2G16 | chr11:63607032 | chr11:63342518 | ENST00000415826 | 3 | 5 | 134_154 | 129.0 | 163.0 | Transmembrane | Helical |
| - Not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000315032 | + | 1 | 18 | 323_362 | 18.0 | 780.0 | Domain | UBA |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000315032 | + | 1 | 18 | 53_304 | 18.0 | 780.0 | Domain | Protein kinase |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000315032 | + | 1 | 18 | 739_788 | 18.0 | 780.0 | Domain | KA1 |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000350490 | + | 1 | 16 | 323_362 | 18.0 | 710.0 | Domain | UBA |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000350490 | + | 1 | 16 | 53_304 | 18.0 | 710.0 | Domain | Protein kinase |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000350490 | + | 1 | 16 | 739_788 | 18.0 | 710.0 | Domain | KA1 |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000361128 | + | 1 | 17 | 323_362 | 18.0 | 720.0 | Domain | UBA |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000361128 | + | 1 | 17 | 53_304 | 18.0 | 720.0 | Domain | Protein kinase |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000361128 | + | 1 | 17 | 739_788 | 18.0 | 720.0 | Domain | KA1 |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000377809 | + | 1 | 18 | 323_362 | 18.0 | 774.0 | Domain | UBA |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000377809 | + | 1 | 18 | 53_304 | 18.0 | 774.0 | Domain | Protein kinase |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000377809 | + | 1 | 18 | 739_788 | 18.0 | 774.0 | Domain | KA1 |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000377810 | + | 1 | 17 | 323_362 | 0 | 692.0 | Domain | UBA |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000377810 | + | 1 | 17 | 53_304 | 0 | 692.0 | Domain | Protein kinase |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000377810 | + | 1 | 17 | 739_788 | 0 | 692.0 | Domain | KA1 |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000402010 | + | 1 | 19 | 323_362 | 18.0 | 789.0 | Domain | UBA |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000402010 | + | 1 | 19 | 53_304 | 18.0 | 789.0 | Domain | Protein kinase |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000402010 | + | 1 | 19 | 739_788 | 18.0 | 789.0 | Domain | KA1 |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000408948 | + | 1 | 16 | 323_362 | 0 | 692.0 | Domain | UBA |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000408948 | + | 1 | 16 | 53_304 | 0 | 692.0 | Domain | Protein kinase |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000408948 | + | 1 | 16 | 739_788 | 0 | 692.0 | Domain | KA1 |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000413835 | + | 1 | 18 | 323_362 | 18.0 | 735.0 | Domain | UBA |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000413835 | + | 1 | 18 | 53_304 | 18.0 | 735.0 | Domain | Protein kinase |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000413835 | + | 1 | 18 | 739_788 | 18.0 | 735.0 | Domain | KA1 |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000508192 | + | 1 | 17 | 323_362 | 18.0 | 725.0 | Domain | UBA |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000508192 | + | 1 | 17 | 53_304 | 18.0 | 725.0 | Domain | Protein kinase |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000508192 | + | 1 | 17 | 739_788 | 18.0 | 725.0 | Domain | KA1 |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000509502 | + | 1 | 18 | 323_362 | 0 | 746.0 | Domain | UBA |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000509502 | + | 1 | 18 | 53_304 | 0 | 746.0 | Domain | Protein kinase |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000509502 | + | 1 | 18 | 739_788 | 0 | 746.0 | Domain | KA1 |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000513765 | + | 1 | 18 | 323_362 | 0 | 756.0 | Domain | UBA |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000513765 | + | 1 | 18 | 53_304 | 0 | 756.0 | Domain | Protein kinase |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000513765 | + | 1 | 18 | 739_788 | 0 | 756.0 | Domain | KA1 |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000315032 | + | 1 | 18 | 59_67 | 18.0 | 780.0 | Nucleotide binding | ATP |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000350490 | + | 1 | 16 | 59_67 | 18.0 | 710.0 | Nucleotide binding | ATP |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000361128 | + | 1 | 17 | 59_67 | 18.0 | 720.0 | Nucleotide binding | ATP |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000377809 | + | 1 | 18 | 59_67 | 18.0 | 774.0 | Nucleotide binding | ATP |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000377810 | + | 1 | 17 | 59_67 | 0 | 692.0 | Nucleotide binding | ATP |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000402010 | + | 1 | 19 | 59_67 | 18.0 | 789.0 | Nucleotide binding | ATP |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000408948 | + | 1 | 16 | 59_67 | 0 | 692.0 | Nucleotide binding | ATP |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000413835 | + | 1 | 18 | 59_67 | 18.0 | 735.0 | Nucleotide binding | ATP |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000508192 | + | 1 | 17 | 59_67 | 18.0 | 725.0 | Nucleotide binding | ATP |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000509502 | + | 1 | 18 | 59_67 | 0 | 746.0 | Nucleotide binding | ATP |
| Hgene | MARK2 | chr11:63607032 | chr11:63342518 | ENST00000513765 | + | 1 | 18 | 59_67 | 0 | 756.0 | Nucleotide binding | ATP |
| Tgene | PLA2G16 | chr11:63607032 | chr11:63342518 | ENST00000323646 | 2 | 4 | 13_129 | 129.0 | 163.0 | Domain | LRAT | |
| Tgene | PLA2G16 | chr11:63607032 | chr11:63342518 | ENST00000415826 | 3 | 5 | 13_129 | 129.0 | 163.0 | Domain | LRAT | |
| Tgene | PLA2G16 | chr11:63607032 | chr11:63342518 | ENST00000323646 | 2 | 4 | 1_133 | 129.0 | 163.0 | Topological domain | Cytoplasmic | |
| Tgene | PLA2G16 | chr11:63607032 | chr11:63342518 | ENST00000415826 | 3 | 5 | 1_133 | 129.0 | 163.0 | Topological domain | Cytoplasmic |
Top |
Fusion Protein-Protein Interaction |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type from validated records (BIOGRID-3.4.160) |
| Gene | PPI interactors |
| Protein-protein interactors based on sequence similarity (STRING) |
| Gene | STRING network |
| MARK2 | |
| PLA2G16 |
| - Retained interactions in fusion protein (protein functional feature from UniProt). |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost interactions due to fusion (protein functional feature from UniProt). |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs to MARK2-PLA2G16 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to MARK2-PLA2G16 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies